Growth arrest induced by C75, a fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma

Cancer Biology and Therapy

Volumn 5, Issue 8, 2006, Pages 978-985

  Gao, Yan ^a   Lin, Li Ping ^a   Zhu, Cai Hua ^a   Chen, Yi ^a   Hou, Yong Tai ^a   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

C75; Cell cycle arrest; Fatty acid synthase; Hepatocellular carcinoma; p38 MAPK; p53; RNA interference

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; C 75; CYCLIN A; CYCLIN B1; CYCLIN D1; FATTY ACID SYNTHASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P53;

ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; RNA INTERFERENCE;

EID: 33751179018     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.8.2883     Document Type: Article

References (36)

1. Evert M, Schneider-Stock R, Dombrowski F. Overexpression of fatty acid synthase in chemically and hormonally induced hepatocarcinogenesis of the rat. Lab Invest 2005; 85:99-108.
2. Semenkovich CF, Coleman T, Goforth R. Physiologic concentrations of glucose regulate fatty acid synthase activity in HepG2 cells by mediating fatty acid synthase mRNA stability. J Biol Chem 1993; 268:6961-70.
3. Baron A, Migita T, Tang D, Loda M. Fatty acid synthase: A metabolic oncogene in prostate cancer? J Cell Biochem 2004; 91:47-53.
4. Innocenzi D, Alo PL, Balzani A, Sebastiani V, Silipo V, La Torre G, Ricciardi G, Bosman C, Calvieri S. Fatty acid synthase expression in melanoma. J Cutan Pathol 2003; 30:23-8.
5. Kuhajda FP. Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology. Proc Natl Acad Sci USA 2000; 16:202-8.
6. Visca P, Alo PL, Del Nonno F, Botti C, Trombetta G, Marandino F, Filippi S, Di Tondo U, Donnorso RP. Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa. Clin Cancer Res 1999; 5:4111-8.
7. Camassei FD, Cozza R, Acquaviva A, Jenkner A, Rava L, Gareri R, Donfrancesco A, Bosman C, Vadala P, Hadjistilianou T, Boldrini R. Expression of the lipogenic enzyme fatty acid synthase (FAS) in retinoblastoma and its correlation with tumor aggressiveness. Invest Ophthalmol Vis Sci 2003; 44:2399-403.
8. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 2003; 63:3799-804.
9. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004; 101:10715-20.
10. Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF, Pizer ES. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 2001; 61:1493-9.
11. Knowles LM, Axelrod F, Browne CD, Smith JW. A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem 2004; 279:30540-5.
12. Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 2004; 24:39-46.
13. Lu S, Archer MC. Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer. Carcinogenesis 2005; 26:153-7.
14. Leonhardt M, Langhans W. Fatty acid oxidation and control of food intake. Physiol Behav 2004; 83:645-51.
15. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87:1973-7.
16. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J, Okamoto E, Hayashi N, Hori M. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998; 27:951-8.
17. Dils R, Carey EM. Fatty acid synthase from rabbit mammary gland. Methods Enzymol 1975; 35:74-83.
18. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003; 63:132-9.
19. Camassei FD, Jenkner A, Rava L, Bosman C, Francalanci P, Donfrancesco A, Alo PL, Boldrini R. Expression of the lipogenic enzyme fatty acid synthase (FAS) as a predictor of poor outcome in nephroblastoma: An interinstitutional study. Med Pediatr Oncol 2003; 40:302-8.
20. Schwartz D, Rotter V. p53-dependent cell cycle control: Response to genotoxic stress. Semin Cancer Biol 1998; 8:325-36.
21. 2/M transition by p53. Oncogene 2001; 20:1803-15.
22. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996; 10:934-47.
23. Schmaltz C, Hardenbergh PH, Wells A, Fisher DE. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol 1998; 18:2845-54.
24. Alessenko AV, Boikov PYa, Filippova GN, Khrenov AV, Loginov AS, Makarieva ED. Mechanisms of cycloheximide-induced apoptosis in liver cells. FEBS Lett 1997; 416:113-6.
25. Pritchard DM, Watson AJ, Potten CS, Jackman AL, Hickman JA. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA 1997; 94:1795-9.
26. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998; 392:405-8.
27. Obata T, Brown GE, Yaffe MB. MAP kinase pathways activated by stress: The p38 MAPK pathway. Crit Care Med 2000; 28:N67-77.
28. Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Oncol 2004; 24:591-608.
29. Fan M, Chambers TC. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 2001; 4:253-67.
30. MacKeigan JP, Taxman DJ, Hunter D, Earp IIIrd HS, Graves LM, Ting JP. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 2002; 8:2091-9.
31. Menendez JA, Vellon L, Colomer R, Lupu R. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int J Cancer 2005; 115(1):19-35.
32. Olson JM, Hallahan AR. p38 MAP kinase: A convergence point in cancer therapy. Trends Mol Med 2004; 10:125-9.
33. Schafer KA. The cell cycle: A review. Vet Pathol 1998; 35:461-78.
34. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif 2003; 36:165-75.
35. Schwartz D, Rotter V. p53-dependent cell cycle control: Response to genotoxic stress. Semin Cancer Biol 1998; 8:325-36.
36. Wu GS. The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 2004; 3:156-61.